Medirom Healthcare Technologies Inc.(MRM)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Limited institutional coverage
Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 5 institutional filers currently hold this stock.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
MRM Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Medirom Healthcare Technologies Inc. (MRM), a Consumer Discretionary sector company. MRM is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 5 institutional filers currently hold this stock. Top institutional holders of MRM by reported 13-F value include UBS Group AG, TWO SIGMA SECURITIES,, GAMMA Investing, based on the most recent SEC filings. MRM trades on the Nasdaq exchange and files with the SEC under CIK 1819704. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MRM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Medirom Healthcare Technologies Inc. directly from SEC EDGAR.
AI Insight: MRM Financial Trends
Debt surged 64% from Q4 2023 to Q4 2024, then stabilized, but equity collapsed 74% in the latest quarter — balance sheet deterioration despite prior recovery.
• Total debt rose from $1,652M (Q4 2023) to $2,497M (Q4 2024), a $845M increase; stabilized at $2,598M by Q2 2025.
• Equity rebounded from negative $59M (Q4 2022) to positive $933M (Q4 2024), then collapsed to $243M in Q2 2025.
⚠ Equity decline of $690M (74%) in six months from Q4 2024 to Q2 2025 suggests material losses or capital adjustments; monitor next earnings.
⚠ Debt-to-equity ratio deteriorated sharply post-Q4 2024; at current leverage, financial flexibility and covenant risk warrant close observation.
AI Insight: MRM Ratio Trends
Debt-to-equity spiked to 10.70x in Q2 2025, the highest in five years, signaling a sharp deterioration in leverage.
• D/E ratio jumped from 2.68x at Q4 2024 to 10.70x by Q2 2025—largest quarterly increase on record.
⚠ D/E now 37% higher than TTM average (10.70x vs. historical 7.8x), suggesting recent debt issuance or equity erosion.
⚠ Profitability and return metrics unavailable; unable to assess whether deteriorating leverage reflects investment or distress.
Get alerted when MRM's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Medirom Healthcare Technologies Inc. including:
Top Institutional Holders of MRM
UBS Group AG
$29.7K26,548 shTWO SIGMA SECURITIES, LLC
$15.7K13,977 shGAMMA Investing LLC
$7.2K6,409 shRHUMBLINE ADVISERS
$2.2K1,984 shHRT FINANCIAL LP
$13.0011,905 sh
| Fund | Value | Shares |
|---|---|---|
| UBS Group AG | $29.7K | 26,548 |
| TWO SIGMA SECURITIES, LLC | $15.7K | 13,977 |
| GAMMA Investing LLC | $7.2K | 6,409 |
| RHUMBLINE ADVISERS | $2.2K | 1,984 |
| HRT FINANCIAL LP | $13.00 | 11,905 |
More Consumer Discretionary Companies
View all Consumer Discretionary →Put MRM on your watchlist
Track score changes the day Medirom Healthcare Technologies Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MRM a good stock to buy?
13F Pro's AI-powered analysis of Medirom Healthcare Technologies Inc. (MRM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Consumer Discretionary sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MRM are available on the MRM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own MRM?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MRM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Medirom Healthcare Technologies Inc.'s investment landscape.